Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

E-resources

PDF

Peer reviewed Open access

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Ball, Brian J.; Famulare, Christopher A.; Stein, Eytan M.; Tallman, Martin S.; Derkach, Andriy; Roshal, Mikhail; Gill, Saar I.; Manning, Benjamin M.; Koprivnikar, Jamie; McCloskey, James; Testi, Rebecca; Prebet, Thomas; Al Ali, Najla H.; Padron, Eric; Sallman, David A.; Komrokji, Rami S.; Goldberg, Aaron D.

Blood advances, 07/2020, Volume: 4, Issue: 13

Journal Article

•Treatment-naive and relapsed/refractory MDS patients receiving venetoclax and HMAs have an ORR of 59% with 63% of responders proceeding to transplant.•Allogeneic stem cell transplantation after treatment with venetoclax in combination with HMA is associated with prolonged survival. Display omitted

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme